- Home
- BCSF vs VTYX Comparison
BCSF vs VTYX Comparison
Compare BCSF & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | VTYX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.5M | 990.9M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCSF | VTYX |
|---|---|---|
| Price | $13.64 | $14.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $15.00 | $13.50 |
| AVG Volume (30 Days) | 391.6K | ★ 5.9M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $278,347,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.20 | $0.78 |
| 52 Week High | $19.21 | $25.00 |
Technical Indicators
Market Signals| Indicator | BCSF | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 76.51 |
| Support Level | $13.46 | $7.08 |
| Resistance Level | $13.87 | $13.90 |
| Average True Range (ATR) | 0.28 | 0.32 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 20.22 | 84.02 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.